In patients with stage @ CKD , adverse events were reported over @ weeks by @ patients ( @ % ) on placebo ( @ severe -LSB- @ % -RSB- and @ serious -LSB- @ % -RSB- ) , @ ( @ % ) on empagliflozin @ mg ( six severe -LSB- @ % -RSB- and six serious -LSB- @ % -RSB- ) and @ ( @ % ) on empagliflozin @ mg ( eight severe -LSB- @ % -RSB- and seven serious -LSB- @ % -RSB- ) .